Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tobevibart + elebsiran
- Development stage
- Unknown
- Lead developer
- Vir Biotechnology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Tobevibart + elebsiran is an investigational combination therapy for chronic hepatitis delta (CHD) and chronic hepatitis B. Tobevibart is a broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen; it inhibits the entry of both hepatitis B virus (HBV) and hepatitis delta virus (HDV) into hepatocytes and reduces circulating viral particles. Elebsiran (also known as VIR-2218) is a small interfering RNA (siRNA) designed to degrade HBV RNA transcripts, thereby limiting production of the hepatitis B surface antigen and exerting direct antiviral activity against both HBV and HDV. Both agents are administered subcutaneously. The combination has demonstrated rapid, deep suppression of HDV RNA in clinical trials, with 100% of participants in the combination arm achieving significant virologic response at week 24 in phase 2 studies. The therapy has received FDA Breakthrough Therapy designation and EMA PRIME designation for CHD[1][3][5][6].
- Other names
- tobevibart-elebsiran
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on tobevibart + elebsiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tobevibart + elebsiran.